A posthoc, exploratory analysis of Look AHEAD data shows that the treatment effect of an intensive lifestyle intervention on the occurrence of MACE varies greatly between patients.
In the RELAX-AHF-2 trial, infusion with serelaxin for 48 hours did not result in decrease in CV mortality at 180 days and HF worsening after 5 days compared to placebo in hospitalized acute HF patients.
Long-term, large study in EPIC-Norfolk cohort finds association of apoB/apoA-I ratio with the risk of aortic valve stenosis incidence, and shows that lp(a) is an independent risk factor for AVS.
ESC HF 2019 TmP/GFR is a novel parameter for tubular function. Lisa Emmens presents findings of her study on determinants of this parameter and its association with outcomes in HF patients.
A science advisory from the American Heart Association (AHA) stated that prescription omega-3 fatty acid medication reduces triglyceride levels by 20-30% in those with high triglyceride levels.
Prof. van der Meer uses a case description to explain the issue of RAASi uptitration in the presence of hyperkalemia in HF. Furthermore, he talks about outcomes and new treatment options in HF patients with hyperkalemia.
In the phase III DAPA-HF trial, treatment with an SGLT2 inhibitor resulted in reduction in the primary composite endpoint of CV death or worsening of HF in patients with HFrEF compared to placebo.
ESC HF 2019 Jozine ter Maaten presents the results of her study on the effects of loop diuretics dosage on the ability to uptitrate RAASi in HFrEF patients and the association of loop diuretics dosage with outcomes.
Discontinuation of digoxin in hospitalized HFrEF patients on more contemporary medical therapy resulted in worse outcomes after 6 months until 4 years after discharge compared to those who stayed on digoxin.
The ELIPSE HoFH trial met its primary endpoint, showing that evinacumab lowered LDL-c by 49% from baseline in HoFH patients already on other lipid-lowering therapies, including PCSK9 inhibitors.
An AI model permits point-of-care identification of individuals with a high likelihood of AF, in normal sinus rhythm ECGs, based on subtle findings due to structural changes in the atria.
Frederik Persson shows evidence of renoprotective effects with GLP-1RA treatment, by discussing various small clinical trials as well as CVOTs with GLP-1RAs.